Heparin and maternal fetal interface: Why should it work to prevent pregnancy complications?
Received 28 July 2009; received in revised form 28 July 2009; accepted 1 August 2009.
Abstract
Anticoagulant therapy has been used extensively for the prevention of recurrent pregnancy losses, and other placenta mediated complications, including prevention of preeclampsia and fetal growth restriction. While heparin anticoagulation is a standard treatment for antiphospholipid antibody syndrome, it is increasingly being used in the prevention of placenta mediated complications. In this article, we explore the role of heparin at maternal-fetal interface, the molecular mechanism of action for heparin, and ongoing basic and translational work being done to elucidate heparin's principal mechanisms of action.
aDepartment of Obstetrics & Gynecology Unit 3, Civil Hospital & Dow University of Health Sciences, Karachi, Pakistan
bDepartment of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, 333 Cedar Street, FMB 339B, New Haven, CT 06520-8063, United States
cYale Women and Children's Center for Blood Disorders, United States
dNational Hemophilia Foundation- Baxter Clinical Fellowship Program at Yale, United States
eDivision of Maternal Fetal Medicine, Yale University School of Medicine, 333 Cedar Street, FMB 339B, New Haven, CT 06520-8063, United States